JP2001525359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001525359A5 JP2001525359A5 JP2000523983A JP2000523983A JP2001525359A5 JP 2001525359 A5 JP2001525359 A5 JP 2001525359A5 JP 2000523983 A JP2000523983 A JP 2000523983A JP 2000523983 A JP2000523983 A JP 2000523983A JP 2001525359 A5 JP2001525359 A5 JP 2001525359A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- human
- xerostomia
- hydrogen
- amifostine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010013781 Dry mouth Diseases 0.000 description 5
- 208000005946 Xerostomia Diseases 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 3
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960001097 Amifostine Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
Description
【特許請求の範囲】
【請求項1】
口内乾燥症を治療するための組成物であって、式:
R1NH(CH2)nNH(CH2)mSR2
(式中、
R1は、水素、C5〜C7アリール、C2〜C7アシルまたはC1〜C7アルキルであり;
R2は、水素、PO3H2またはR3(ここでR3は、R1NH(CH2)nNH(CH2)mS−である)であり;
nは、1〜10の整数であり、
mは、1〜10の整数である)
で表される化合物または製剤学的に許容可能なその付加塩もしくは水和物を有効成分として含む組成物。
【請求項2】
口内乾燥症を治療するための組成物であって、式:
R−NH−(CnH2n)−NH−(CmH2m)−S−PO3H2
(式中、
Rは、水素、または1〜7個の炭素原子を有するアルキル基であり、
mおよびnは、互いに独立して、1〜10の値である)
で表される化合物または製剤学的に許容可能なその付加塩もしくは水和物を有効成分として含む組成物。
【請求項3】
化合物がアミホスチンである、請求項1に記載の組成物。
【請求項4】
化合物がアミホスチンである、請求項2に記載の組成物。
【請求項5】
口内乾燥症が、ヒトへの治療薬の投与またはヒトの放射線への曝露に伴うものである、請求項1〜4のいずれか1項に記載の組成物。
【請求項6】
口内乾燥症が、ヒトへの治療薬の投与またはヒトの放射線への曝露に伴うものであり、ヒトにおける口内乾燥症の発生後に投与される、請求項1〜4のいずれか1項に記載の組成物。
【予納台帳番号】 015244
【納付金額】 3200
【請求項1】
口内乾燥症を治療するための組成物であって、式:
R1NH(CH2)nNH(CH2)mSR2
(式中、
R1は、水素、C5〜C7アリール、C2〜C7アシルまたはC1〜C7アルキルであり;
R2は、水素、PO3H2またはR3(ここでR3は、R1NH(CH2)nNH(CH2)mS−である)であり;
nは、1〜10の整数であり、
mは、1〜10の整数である)
で表される化合物または製剤学的に許容可能なその付加塩もしくは水和物を有効成分として含む組成物。
【請求項2】
口内乾燥症を治療するための組成物であって、式:
R−NH−(CnH2n)−NH−(CmH2m)−S−PO3H2
(式中、
Rは、水素、または1〜7個の炭素原子を有するアルキル基であり、
mおよびnは、互いに独立して、1〜10の値である)
で表される化合物または製剤学的に許容可能なその付加塩もしくは水和物を有効成分として含む組成物。
【請求項3】
化合物がアミホスチンである、請求項1に記載の組成物。
【請求項4】
化合物がアミホスチンである、請求項2に記載の組成物。
【請求項5】
口内乾燥症が、ヒトへの治療薬の投与またはヒトの放射線への曝露に伴うものである、請求項1〜4のいずれか1項に記載の組成物。
【請求項6】
口内乾燥症が、ヒトへの治療薬の投与またはヒトの放射線への曝露に伴うものであり、ヒトにおける口内乾燥症の発生後に投与される、請求項1〜4のいずれか1項に記載の組成物。
【予納台帳番号】 015244
【納付金額】 3200
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/987,550 | 1997-12-09 | ||
US08/987,550 US5994409A (en) | 1997-12-09 | 1997-12-09 | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
PCT/US1998/026096 WO1999029312A1 (en) | 1997-12-09 | 1998-12-09 | Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006064774A Division JP2006188532A (ja) | 1997-12-09 | 2006-03-09 | アミノチオール化合物を用いた、神経及び腎障害ならびに治療に伴う毒性の治療方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001525359A JP2001525359A (ja) | 2001-12-11 |
JP2001525359A5 true JP2001525359A5 (ja) | 2006-05-11 |
Family
ID=25533362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000523983A Pending JP2001525359A (ja) | 1997-12-09 | 1998-12-09 | アミノチオール化合物を用いた、神経及び腎障害ならびに治療に伴う毒性の治療方法 |
JP2006064774A Pending JP2006188532A (ja) | 1997-12-09 | 2006-03-09 | アミノチオール化合物を用いた、神経及び腎障害ならびに治療に伴う毒性の治療方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006064774A Pending JP2006188532A (ja) | 1997-12-09 | 2006-03-09 | アミノチオール化合物を用いた、神経及び腎障害ならびに治療に伴う毒性の治療方法 |
Country Status (13)
Country | Link |
---|---|
US (7) | US5994409A (ja) |
EP (2) | EP1039887B1 (ja) |
JP (2) | JP2001525359A (ja) |
CN (1) | CN1161113C (ja) |
AT (1) | ATE326956T1 (ja) |
AU (1) | AU739068B2 (ja) |
BR (1) | BR9813524A (ja) |
CA (1) | CA2313089C (ja) |
DE (1) | DE69834658T2 (ja) |
DK (1) | DK1039887T3 (ja) |
ES (1) | ES2260857T3 (ja) |
PT (1) | PT1039887E (ja) |
WO (1) | WO1999029312A1 (ja) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0954283B1 (en) * | 1996-12-30 | 2007-03-21 | Battelle Memorial Institute | Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation |
US6573253B2 (en) | 1997-02-12 | 2003-06-03 | Medimmune Oncology Inc. | Methods for the administration of amifostine and related compounds |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US6239119B1 (en) * | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
US7314637B1 (en) | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
US6384259B1 (en) * | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
WO2001070220A1 (en) * | 2000-03-22 | 2001-09-27 | Neopharm, Inc. | A method of administering liposomal encapsulated taxane |
KR20030014208A (ko) * | 2000-04-26 | 2003-02-15 | 오레곤 헬스 사이언시즈 유니버시티 | 티올계 화학보호제 화합물의 투여 |
EP1289556B1 (en) * | 2000-06-14 | 2007-06-06 | The United States of America, represented by The Secretary, Dept. of Health and Human Services, the Natl. Institutes of Health | Isoflavones against radiation-induced mortality |
EP1365803A2 (en) * | 2000-08-30 | 2003-12-03 | Oregon Health and Science University | Chemoprotectant for gastric toxicity |
WO2002041837A2 (en) * | 2000-11-22 | 2002-05-30 | Rxkinetix, Inc. | Treatment of mucositis |
US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
JP2005510471A (ja) * | 2001-09-24 | 2005-04-21 | トスク インコーポレーティッド | 減少した毒性のシスプラチン製剤及びそれを使用する方法 |
CN100391941C (zh) * | 2001-12-07 | 2008-06-04 | 海门慧聚药业有限公司 | 一种胺基硫醇及其硫代衍生物 |
AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
US7345018B2 (en) | 2002-04-25 | 2008-03-18 | Reception Aps | Method of treating side effects induced by therapeutic agents |
US7981928B2 (en) * | 2002-09-05 | 2011-07-19 | Nanodynamics, Inc. | Chemotherapy method using x-rays |
WO2004039336A2 (en) * | 2002-10-31 | 2004-05-13 | Oregon Health & Science University | Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
MXPA05008284A (es) * | 2003-02-03 | 2006-03-21 | Neopharm Inc | Taxano y otros farmacos antineoplasicos encapsulados, liposomicos, estables, susceptibles de esterilizacion por filtracion. |
WO2004080429A2 (en) * | 2003-03-13 | 2004-09-23 | Oregon Health & Science University | Use of thiol-based compositions in ameliorating mucosal injury |
US8580321B2 (en) * | 2003-12-02 | 2013-11-12 | The Cleveland Clinic Foundation | Method for reducing the effects of chemotherapy using flagellin related polypeptides |
US20050187608A1 (en) * | 2004-02-24 | 2005-08-25 | O'hara Michael D. | Radioprotective compound coating for medical devices |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
CA2584138A1 (en) * | 2004-10-18 | 2006-04-27 | Raphael C. Lee | Methods and compositions for treatment of free radical injury |
US20070082858A1 (en) * | 2004-12-21 | 2007-04-12 | Oregon Health & Science University | Methods and compositions for the prevention of toxic side effects of aminoglycoside medications |
EP2460534A1 (en) | 2004-12-22 | 2012-06-06 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
US7658913B2 (en) | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
JP2009517402A (ja) * | 2005-11-28 | 2009-04-30 | ディー. ロウェ,バーノン | 腎毒性の低減に有用な組成物及びその使用方法 |
US9585849B2 (en) | 2006-04-17 | 2017-03-07 | The Burlington Hc Research Group, Inc. | Broad spectrum antiviral and methods of use |
EP2010166B1 (en) * | 2006-04-17 | 2013-11-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Organic disulfide antiretroviral agents |
US8138227B2 (en) * | 2006-07-06 | 2012-03-20 | Trustees Of Dartmouth College | Method for inhibiting or reversing non-enzymatic glycation |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
WO2008060441A2 (en) * | 2006-11-09 | 2008-05-22 | Scidose Llc | Stable amifostine liquid concentrate |
WO2008119032A1 (en) * | 2007-03-27 | 2008-10-02 | Perscitus Biosciences, Llc | Compositions and methods for protecting cells from toxic exposures |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
US8372389B2 (en) * | 2007-11-28 | 2013-02-12 | Hadasit Medical Research Services And Development Ltd. | Methods for the treatment of radiation or chemotherapy-induced tissue damage |
WO2009113984A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
WO2010014957A1 (en) | 2008-08-01 | 2010-02-04 | Cleveland Biolabs, Inc. | Methods for treating reperfusion injuries |
CN101347412B (zh) * | 2008-09-02 | 2011-07-27 | 大连美罗药业股份有限公司 | 三水合氨磷汀结晶冻干制剂及其制备方法 |
CA2824438A1 (en) | 2011-01-10 | 2012-07-19 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
WO2012103520A1 (en) * | 2011-01-28 | 2012-08-02 | Board Of Regents Of The University Of Nebraska | Methods and compositions for modulating cyclophilin d |
TWI568453B (zh) * | 2011-11-22 | 2017-02-01 | 原創生醫股份有限公司 | 具有螯合型複合微胞之藥物載體及其應用 |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
WO2014204854A1 (en) * | 2013-06-18 | 2014-12-24 | Aminomdix Inc. | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids |
CN107087411B (zh) | 2014-07-30 | 2021-06-29 | 基因组保护股份有限公司 | 鞭毛蛋白组合物及用途 |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
CN107753490B (zh) * | 2017-11-19 | 2018-07-27 | 宋在明 | 一种治疗肿瘤放疗所致口腔黏膜炎的透皮给药制剂 |
US20220259164A1 (en) * | 2019-06-13 | 2022-08-18 | Shanghai Kechow Pharma, Inc. | Use of aminothiol compounds as cerebral nerve or heart protective agent |
CN114712350B (zh) * | 2021-12-28 | 2024-04-12 | 中国医学科学院放射医学研究所 | Dttz在制备预防、治疗化疗损伤药物中的应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3892824A (en) * | 1968-12-16 | 1975-07-01 | Southern Res Inst | S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates |
US4424216A (en) * | 1979-07-31 | 1984-01-03 | The Rockefeller University | Method for the reduction of mucin viscosity |
US4742050B1 (en) | 1982-08-17 | 1994-06-28 | Alpha Therapeutic Corp | Sensitization of hypoxic tumor cells and control of growth thereof |
US4656034A (en) | 1985-05-20 | 1987-04-07 | Survival Technology, Inc. | Absorption enhancing agents |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
MY102796A (en) | 1987-04-15 | 1992-10-31 | Freezone Pty Ltd | A tyre bead breaker |
US5091180A (en) | 1987-11-20 | 1992-02-25 | Administrators Of The Tulane Educational Fund | Protection against rhabdomyolysis-induced nephrotoxicity |
AU629533B2 (en) * | 1987-12-22 | 1992-10-08 | U.S. Bioscience, Inc. | Improving toxicity profiles in chemotherapy |
US5112954A (en) | 1988-02-26 | 1992-05-12 | Neorx Corporation | Method of enhancing the effect of cytotoxic agents |
JPH04505760A (ja) * | 1989-05-24 | 1992-10-08 | ユー・エス・バイオサイエンス | Aztの副作用および毒性からの保護方法 |
US5167947A (en) | 1989-10-26 | 1992-12-01 | Southwest Research Institute | Enhancement of absorption of radioprotective drugs |
US5217964A (en) | 1991-01-23 | 1993-06-08 | Merrell Dow Pharmaceuticals Inc. | Polyamine thiols as radioprotective agents |
US5554655A (en) * | 1991-09-30 | 1996-09-10 | Jess G. Thoene | Method of treating HIV infection |
US5567686A (en) * | 1992-03-13 | 1996-10-22 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
US5869338A (en) * | 1992-03-13 | 1999-02-09 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
US5488042A (en) * | 1992-03-13 | 1996-01-30 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
US5618823A (en) | 1992-06-24 | 1997-04-08 | Boehringer Mannheim Italia S.P.A. | Glutathione as chemoprotective agent |
US5424471A (en) * | 1992-07-31 | 1995-06-13 | U.S. Bioscience, Inc. | Crystalline amifostine compositions and methods of the preparation and use of same |
SG47101A1 (en) * | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
DE4234257A1 (de) * | 1992-10-10 | 1994-04-14 | Roehm Gmbh | Verfahren zur Herstellung von Thiol(meth)acrylaten |
KR100311851B1 (ko) | 1993-02-23 | 2002-04-24 | 슈테펜엘.네스비트 | 방사선보호제로서의폴리아민유도체 |
US5824664A (en) * | 1993-03-26 | 1998-10-20 | U.S. Bioscience, Inc. | Suppression of HIV expression by organic thiophosphate |
CA2124021A1 (en) | 1993-05-21 | 1994-11-22 | John Samonides Sr. | Adhesive for labels and the like |
AU679236B2 (en) | 1993-05-26 | 1997-06-26 | Merrell Dow Pharmaceuticals Inc. | N-alkylthio polyamine derivatives as radioprotective agents |
CA2099070A1 (en) | 1993-06-23 | 1994-12-24 | Nelson Mak | Process and apparatus for deinking wastepaper with molten fatty acid |
US5467947A (en) * | 1994-04-08 | 1995-11-21 | Metra Electronics Corporation | Mounting kit for mounting one of several types of audio equipment in an automotive dashboard |
US5846958A (en) * | 1995-02-17 | 1998-12-08 | U.S. Bioscience, Inc. | Methods of using aminothiols to promote hematopoietic progenitor cell growth |
GB9504995D0 (en) * | 1995-03-11 | 1995-04-26 | Zeneca Ltd | Compositions |
US6106866A (en) | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
US5974409A (en) * | 1995-08-23 | 1999-10-26 | Microsoft Corporation | System and method for locating information in an on-line network |
WO1997011667A2 (en) * | 1995-09-25 | 1997-04-03 | Samir Chachoua | Therapeutic applications using horse serum |
US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
US6110891A (en) | 1996-06-21 | 2000-08-29 | Alizyme Therapeutics Ltd. | Lectin compositions and uses thereof |
US5866591A (en) | 1996-09-11 | 1999-02-02 | Glaxo Wellcome Inc. | Stable formulations of remifentanil |
US6573253B2 (en) * | 1997-02-12 | 2003-06-03 | Medimmune Oncology Inc. | Methods for the administration of amifostine and related compounds |
US6051563A (en) * | 1997-02-12 | 2000-04-18 | U.S. Bioscience, Inc. | Methods for the administration of amifostine and related compounds |
US5919934A (en) | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
FR2761606B1 (fr) | 1997-04-08 | 1999-05-14 | Cird Galderma | Utilisation de derives aminothiolesters dans le domaine pharmaceutique |
US6284259B1 (en) * | 1997-11-12 | 2001-09-04 | The Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus Gram positive bacteria |
US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
WO1999030705A1 (en) | 1997-12-16 | 1999-06-24 | William Darwin Garner | Reduction of uv induced skin cancer by topical amines |
JPH11240252A (ja) | 1997-12-22 | 1999-09-07 | Tdk Corp | 光記録媒体 |
US6239119B1 (en) * | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
US6384259B1 (en) * | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
US6407278B2 (en) * | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
US6054622A (en) | 1998-12-18 | 2000-04-25 | Alliedsignal Inc | Aromatic hydroxythiol synthesis using diazonium salts |
US6075053A (en) | 1999-02-09 | 2000-06-13 | Bionumerik Pharmaceuticals, Inc. | Method of reducing or reversing neuropathy |
US6489312B1 (en) * | 1999-06-15 | 2002-12-03 | Medimmune Oncology, Inc. | Pharmaceutical formulations comprising aminoalkyl phosphorothioates |
-
1997
- 1997-12-09 US US08/987,550 patent/US5994409A/en not_active Expired - Lifetime
-
1998
- 1998-12-09 DE DE69834658T patent/DE69834658T2/de not_active Expired - Lifetime
- 1998-12-09 JP JP2000523983A patent/JP2001525359A/ja active Pending
- 1998-12-09 ES ES98962011T patent/ES2260857T3/es not_active Expired - Lifetime
- 1998-12-09 PT PT98962011T patent/PT1039887E/pt unknown
- 1998-12-09 AU AU17184/99A patent/AU739068B2/en not_active Expired
- 1998-12-09 WO PCT/US1998/026096 patent/WO1999029312A1/en active IP Right Grant
- 1998-12-09 EP EP98962011A patent/EP1039887B1/en not_active Expired - Lifetime
- 1998-12-09 AT AT98962011T patent/ATE326956T1/de active
- 1998-12-09 CA CA2313089A patent/CA2313089C/en not_active Expired - Fee Related
- 1998-12-09 CN CNB988135442A patent/CN1161113C/zh not_active Expired - Fee Related
- 1998-12-09 BR BR9813524-4A patent/BR9813524A/pt not_active Application Discontinuation
- 1998-12-09 DK DK98962011T patent/DK1039887T3/da active
- 1998-12-09 EP EP05003650A patent/EP1537861A3/en not_active Withdrawn
-
1999
- 1999-10-28 US US09/429,290 patent/US6586476B1/en not_active Expired - Lifetime
-
2002
- 2002-05-03 US US10/137,686 patent/US7105575B2/en not_active Expired - Lifetime
-
2005
- 2005-10-25 US US11/258,335 patent/US20060040903A1/en not_active Abandoned
-
2006
- 2006-03-09 JP JP2006064774A patent/JP2006188532A/ja active Pending
- 2006-08-09 US US11/501,949 patent/US20060270636A1/en not_active Abandoned
-
2010
- 2010-12-08 US US12/963,574 patent/US20110166108A1/en not_active Abandoned
-
2012
- 2012-11-29 US US13/689,652 patent/US20130090312A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001525359A5 (ja) | ||
JP2001526218A5 (ja) | ||
JP2003501488A5 (ja) | ||
RU2000102359A (ru) | Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты | |
CA2392973A1 (en) | Benzoimidazole derivatives useful as antiproliferative agents | |
JP2002525329A5 (ja) | ||
JP2002539128A5 (ja) | ||
JP2006507220A5 (ja) | ||
RU2003101319A (ru) | Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты | |
JP2002519425A5 (ja) | ||
JP2003532640A5 (ja) | ||
JP2001513567A5 (ja) | ||
RU2003134629A (ru) | Соединения цефема | |
GR3025207T3 (en) | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | |
JP2004523478A5 (ja) | ||
US5262149A (en) | Method of treating or preventing alopecia | |
ZA887410B (en) | Polyamine derivatives as antineoplastic agents | |
RU96103685A (ru) | 1,2,5-тиадиазольные производные индолилалкил-пиридинил- и пиримидинил-пиперазинов, способ лечения или предотвращения развития сосудистой головной боли и фармацевтическая композиция | |
HUT70531A (en) | Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them | |
GR78771B (ja) | ||
RU98104276A (ru) | Новые конденсированные изохинолины в качестве лигандов для допаминовых рецепторов | |
JP2002526550A5 (ja) | ||
JP2003509494A5 (ja) | ||
CA2523253A1 (en) | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists | |
JP2005506324A5 (ja) |